Asia Pacific Diagnostic Labs Market Size, Share, By Lab Type, Testing Services, Diseases, Revenue Source, and Country - Trends, Analysis, and Forecast till 2035

• The market is extrapolated to enlarge at USD 22.6 billion in 2035.
• In 2024, the Asia pacific diagnostic labs market size was worth USD 14.7 billion.
• The market is growing at a CAGR of 3.4%.

Diagnostic laboratory is a facility, which is equipped with reagents, apparatus for performing diagnostic test and for detecting human infection. The market is strongly influenced by the boosting healthcare industries, rapid test kits, and soaring scores of persistent conditions. Apart from these factors, escalating rates of allergic diseases also boosts the diagnostic labs market growth in Asia Pacific. Furthermore, collusion and partnerships between companies, which assists to accomplish growth are anticipated to create opportunities over the forecast period.

Key Takeaways:

• China hegemonies the market on grounds of senescent population.
• For instance, according to the data published by Government of China in October 2024, China's population aged 60 and above reached nearly 297 million in 2023, accounting for 21.1% of the total.

Key Drivers of Target Market:

Rising Number of Aging Population Expected to Pitch the Market Growth

Increasing number of aging population in Asia Pacific region can drive the Asia Pacific diagnostic labs market growth as older people are most likely to have chronic diseases, such as diabetes, cardiovascular diseases, cancer, osteoporosis, and others, which need regular diagnostic tests.

• For instance, according to the data published by Economic & Social Commission for Asia & the Pacific, in July 2022, the Asia Pacific population is ageing faster than any other region in the world. There are now 630 million people aged 60 years or above, representing 60% of the world’s older population. By 2050, their number is projected to increase to 1.3 billion. The majority of older persons are women; comprise of up to 61% in the age group of 80 years or over.

Restraints:

Market Growth is Hindered by Infrastructure Limitations of Diagnostic Labs

Infrastructure limitations of diagnostic labs including requirement of more space & infrastructure, 2550mm wide internal corridors, minimum clear ceiling height of 3000 mm, exit lobby, cost of supplies, risk of downtime, and others which can limits growth of target market.

Counterbalance Statements: Clearly, greater laboratory automation is one way of reducing the dependence on staff while minimizing the risk of potentially audit-failing human errors. Additionally, prioritize compliance with the Clinical Laboratory Improvement Amendments (CLIA) regulations, establish a team or designate a compliance officer responsible for staying up-to-date with regulatory changes, regular training sessions for staff on regulatory compliance and quality control practices, and others are some of the solutions over challenges faced by diagnostic labs.

Opportunities:

Sophisticated Technologies can Unlock Growth Potential in Impending Years

The diagnostic labs sector has undergone a radical transformation in recent years due to new innovations and technological advancements. Advanced technologies, such as laboratory automation, digital PCR, next generation sequencing, computed tomography scan, tissue diagnostic equipment, glucose monitoring wearable, and others are used in diagnostic labs to modernize labs, improve operational efficiency, creating images of deep internal structures of the body, detection of genetic markers, and molecular analysis of tissues.

• For instance, in May 2024, Beckman Coulter Diagnostics, a global leader in clinical diagnostics, and MeMed, a leader in the emerging field of advanced host-response technologies, announced expansion of their host immune response diagnostics partnership. This new distribution agreement complements the existing joint effort to develop a MeMed BV-based test for Beckman Coulter's family of Access Immunoassay Analyzers.

The market is classified into lab type, testing services, diseases, revenue source, and country.

Lab Type

Single/independent laboratories, hospital-based labs, physician office labs, and other lab types are various sections into which the market is fractionated. Among these, the hospital-based labs have mastery over the market due to the high volume of patients.

• For instance, in October 2024, The BBMP has decided to establish health kiosks at its Namma Clinics, where 64 diagnostic tests will be conducted for free. The public can undergo various tests, including blood, blood glucose, hemoglobin, and others. 

Testing Services

The classification of market via testing services is distributed into physiological function testing, general & clinical testing, esoteric testing, specialized testing, non-invasive testing, COVID-19 testing, and others. The COVID-19 testing dominate Asia pacific diagnostic labs market share attributable to pandemic which lead to speedy growth in infected cases.

• For instance, in December 2022, The Ministry of Health of Tonga opened a new laboratory in Vaiola Hospital with support from the World Health Organization (WHO) and funding from the Government of India via the United Nations Office for South-South Cooperation (UNOSSC). The laboratory has capacity for real-time polymerase chain reaction (RT-PCR) COVID-19 testing. 

Diseases

With respect to diseases, the market is grouped into cardiology, oncology, neurology, orthopedics, gastroenterology, gynecology, odontology, and others. Although, oncology section grabbed the enormous share of the market owing to increasing cases of cancer diseases cause by unhealthy lifestyle. 

• For instance, in December 2024, Metropolis Healthcare, has announced the acquisition of Core Diagnostics, a specialized diagnostics company headquartered in Delhi NCR. The acquisition is set to enhance Metropolis’ advanced cancer testing capabilities and expand its presence in Northern and Eastern India.

Revenue Source

By revenue source, the market is classified into healthcare plan, out-of-pocket, public system, and others. The healthcare plan influence the target market as it proffer coverage for various types of ailments and surgeries

Asia Pacific Diagnostic Labs Market Report Scope:

Segmentation:

By Lab Type:

• Single/Independent Laboratories
• Hospital-Based Labs
• Physician Office Labs
• Others

By Testing Services:

• Physiological Function Testing
• General & Clinical Testing
• Esoteric Testing
• Specialized Testing
• Non-Invasive Testing
• COVID-19 Testing
• Others

By Diseases:

• Cardiology
• Oncology
• Neurology
• Orthopedics
• Gastroenterology
• Gynecology
• Odontology
• Others

By Revenue Source:

• Healthcare Plan
• Out-of-Pocket
• Public System

By Region:

• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia-Pacific

The companies administering in market include HEALTHIANS.COM, Pathkind Diagnostics Pvt. Ltd., PATHOLOGY ASIA, Redcliffe labs, and others. Many market players are adopting strategies, such as benchmarking survey, strategic collaborations, launching new manufacturing site, and other for the purpose of market expansion.

List of Key Players in the Market:

• HEALTHIANS.COM
• Pathkind Diagnostics Pvt. Ltd.
• PATHOLOGY ASIA
• Redcliffe labs
• RELIANCE MEDLAB
• APMD
• GenePath Diagnostics
• STERLING ACCURIS WELLNESS PVT. LTD.
• METROPOLIS HEALTHCARE LIMITED
• Dr Reddys Path Labs  Private Limited

• In August 2024, Unilabs, a leading international provider of diagnostic services, and C2N Diagnostics, LLC, a specialist in advanced diagnostic solutions in the field of Alzheimer’s disease and related neurological disorders, have signed a multi-year partnership agreement. This agreement will increase the access to C2N’s Precivity portfolio of blood tests on an exclusive basis in Europe, including Norway, Switzerland, and the United Kingdom. 
• In March 2024, The World Health Organization (WHO) published recommendations on the use of a new class of diagnostic technologies, including the targeted next-generation sequencing (NGS) tests for the diagnosis of drug-resistant tuberculosis (TB) in the third edition of the consolidated guidelines on tuberculosis. Module 3: Diagnosis. 

More Related Reports

Influenza Diagnostic Equipment Market
Diagnostic Labs Market
Enterprise Digital Labs Market
Thermoplastic Vulcanizate (TPV) Market
Food Diagnostics System Market